Tong Ren Tang Technologies Co (TGRNF) Fair Value & Analysis
Healthcare · US · Market cap $634M
Tong Ren Tang Technologies Co
TGRNF · US
Fair value as of: Jul 5, 2026
From 26 valuation models · updated 17 days ago
Fair value updated Jul 5, 2026, revised from $4.74 to $0.9800 (−79.3%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.4940 – $1.35 · fair‑value band $0.7300 – $1.22 · the $0.4949 price screens below the $0.9800 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Tong Ren Tang Technologies Co (TGRNF) currently trades at $0.4949, while our model-based Fair Value estimate is $0.9800, implying the stock looks roughly 98.0% undervalued today. We read business quality at 47/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Tong Ren Tang Technologies Co generated revenue of $6.5B at a net margin of 6.1%. Revenue declined 14.5% year over year. It earns a return on equity of 6.5%. The balance sheet holds a net cash position of $2.7B. Fundamentals as of Jul 5, 2026
Our scenario range runs from $0.7300 (bear case) to $1.22 (bull case); at $0.4949, the current price sits below that range. The share trades about 29% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -44% fair-value upside, at 98%, TGRNF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through three segments: The Company; Tong Ren Tang Chinese Medicine; and Others. The company develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products. It also offers ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, and cosmetics. In addition, it provides medical research and development; advertisement; and Chinese medical consultations and treatments. Further, the company produces and processes biochemical products; extracts and processes plants; and offers medical services. Tong Ren Tang Technologies Co. Ltd. was founded in 1669 and is based in Beijing, the People's Republic of China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Tong Ren Tang Technologies Co reported revenue of $6.3B in FY2025 versus $5.4B in FY2021, a compound +4.0%/yr. Reported net income was $386M in FY2025, compounding −6.6%/yr from FY2021.
Is TGRNF fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc ABBV | $224.94 | $109.04 | -52% |
| Roche Holding 1RO | €377.80 | €280.03 | -26% |
| Merck & Co MRCK34 | R$72.90 | R$13.54 | -81% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| AstraZeneca PLC ZEG | €160.70 | €86.60 | -46% |
| Novo Nordisk A/S NOVOB | kr 283.10 | kr 404.89 | +43% |
| Amgen Inc AMGN34 | R$64.32 | R$8.51 | -87% |
| Gilead Sciences, Inc GILD | 2,263 MXN | 125.09 MXN | -94% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Tong Ren Tang Technologies Co (TGRNF) undervalued?
What is the fair value of TGRNF?
What is the quality score of TGRNF?
What is the revenue of Tong Ren Tang Technologies Co (TGRNF)?
What is the net profit margin of TGRNF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Tong Ren Tang Technologies Co analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.